Table 2.
Extrahepatic therapeutic compounds
| Name | Mechanism | Exp Phase | Ref |
|---|---|---|---|
| Serelaxin | NO release | Phase II | [183] |
| Sorafenib | Tyrosine kinase inhibitor | Phase II | [179] |
| Albumin | Anti-inflammatory | Phase III | [184] |
| Metformin | Insulin sensitizer, anti-inflammatory | Phase IV | [185] |
| Fasudil | Rho-kinase inhibitor | Pre-clinical | [186] |
| Rapamycin | mTOR complex 1 inhibitor | Pre-clinical | [187] |
| t-TUCB | Soluble epoxide hydrolase inhibitor | Pre-clinical | [188] |
| Cerium oxide nanoparticles | Anti-inflammatory | Pre-clinical | [189] |
| Bifidobacterium pseudocatenulatum CECT7765 | Anti-BT translocation | Pre-clinical | [190] |
| Probiotics (VSL#3) | Anti-BT translocation | Pre-clinical | [191] |